Sartorius’ Post

View organization page for Sartorius, graphic

178,577 followers

Have you ever heard of the mosquito-borne chikungunya virus? According to the WHO, more than two million cases of chikungunya infections, which cause flu-like symptoms and severe joint pain, have been reported since 2005. No vaccine was available against the virus – until Sartorius’ customer Valneva had their vaccine approved by the FDA in late 2023. Learn more on the Sartorius blog about how we are part of the solution and how recombinant albumin from Albumedix now a part of Sartorius, stabilizes the vaccine during storage and transport: https://sar.to/voytu #PartOfTheSolution #SimplifyingProgress #Bioprocessing #BetterHealth

Part of the Solution: How Recombinant Albumin Supports the World’s First Chikungunya Vaccine

Part of the Solution: How Recombinant Albumin Supports the World’s First Chikungunya Vaccine

Jalil Hakimi

Senior Consultant Business Development and Partnership Executive MBA- Ivey Business School- Western University-Canada

1mo

Thank you Severo for sharing this fact! I have personally used Albumedix products in the past for Vaccine development and they are incredibly high quality and great value for new product development specially at pharmaceutical grade!

To view or add a comment, sign in

Explore topics